Fundraising FoxRubrYc Therapeutics
San Ramon, US · Founded 2017 · Delaware corporation · 3 known investors
Find your way into RubrYc Therapeutics
Sign up to see every warm intro you have to RubrYc Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the RubrYc Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets. The company focuses on therapeutic development for patients with limited treatment options.
Founders & leadership
Investors · 3
How we know: Third Point Ventures's portfolio page · funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
How we know: funding news · press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$9.5M disclosed across 3 rounds · 2018–2019
▶$2.3MraisedJul 2019 · 10 investors · BiotechnologyRule 506(b)
- Bill ColstonExecutive Officer, Director, Promoter
- Isaac J. BrightExecutive Officer, Director
- Jason HongDirector
- Paul ConleyDirector
- Jean ViretDirector
- Offering amount
- $7.5M
- Amount sold
- $2.3M
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5.3MraisedApr 2018 · 8 investors · BiotechnologyRule 506(b)
- Jason HongDirector
- Isaac J. BrightExecutive Officer, Director
- Paul ConleyDirector
- Bill ColstonExecutive Officer, Director, Promoter
- Offering amount
- $8.3M
- Amount sold
- $5.3M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.9MraisedApr 2018 · 1 investors · BiotechnologyRule 506(b)
- Paul ConleyDirector
- Bill ColstonExecutive Officer, Director, Promoter
- Jason HongDirector
- Isaac J. BrightExecutive Officer, Director
- Offering amount
- $1.9M
- Amount sold
- $1.9M
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does RubrYc Therapeutics do?
- Rubryc discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies for hard-to-drug targets. The company focuses on therapeutic development for patients with limited treatment options.
- Who are RubrYc Therapeutics's investors?
- RubrYc Therapeutics's investors include Third Point Ventures, Paladin Capital Group, Vital Venture Capital.
- How much funding has RubrYc Therapeutics raised?
- RubrYc Therapeutics has disclosed $9.5M raised across 3 rounds.
- Where is RubrYc Therapeutics headquartered?
- RubrYc Therapeutics is headquartered in San Ramon, US.